Sign Up Now!
To sign up for our newsletter or print publications, please enter your contact information below.
First Name *
Last Name *
Email Address (Verify) *
We will request your mailing address on the next page.
We will request your mailing address on the next page.

JHOP - August 2021 Vol 11, No 4 - FDA Updates
Download PDF

On May 28, 2021, the FDA accelerated the approval of infigratinib (Truseltiq; QED Therapeutics), an oral kinase inhibitor, for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma (CCA) and FGFR2 fusion or other rearrangement, as detected by an FDA-approved test.

The FDA granted infigratinib priority and fast-track review, as well as orphan drug designation for this indication. Infigratinib is the second targeted therapy approved by the FDA for this patient population.

On the same day, the FDA approved the FoundationOne CDx test as a companion diagnostic to infigratinib for selecting patients with CCA and FGFR2 fusion or other rearrangement for infigratinib treatment.

The approval of infigratinib was based on results from CBGJ398X2204, a multicenter, open-label, single-arm clinical trial of 108 patients with previously treated, unresectable locally advanced or metastatic CCA and an FGFR2 fusion or rearrangement. Patients received infigratinib 125 mg once daily for 21 days, followed by 7 days off, in 28-day cycles, until disease progression or unacceptable side effects.

The primary end points were overall response rate (ORR) and duration of response (DOR). The ORR was 23% (95% confidence interval [CI], 16-32), including 1 complete response and 24 partial responses. The median DOR was 5 months (95% CI, 3.7-9.3). Among the 23 patients who responded to therapy, the DOR was ≥6 months in 8 patients.

The most common (≥20%) adverse reactions were hyperphosphatemia, increased creatinine, nail toxicity, stomatitis, dry eye, fatigue, alopecia, palmar-plantar erythrodysesthesia syndrome, arthralgia, dysgeusia, constipation, abdominal pain, dry mouth, eyelash changes, diarrhea, dry skin, decreased appetite, blurred vision, and vomiting. Grade 3 or 4 adverse events included hyperphosphatemia and retinal pigment epithelial detachment.

Continued approval for this indication may be contingent on clinical benefit in confirmatory trial(s).

Related Items
Tivdak First Antibody–Drug Conjugate FDA Approved for Recurrent or Metastatic Cervical Cancer
JHOP - October 2021 Vol 11, No 5 published on October 14, 2021 in FDA Updates
Exkivity Novel Oral Targeted Therapy Approved for Metastatic NSCLC with EGFR Exon 20 Insertion Mutations
JHOP - October 2021 Vol 11, No 5 published on October 14, 2021 in FDA Updates
Pylarify Second Radioactive Imaging Drug FDA Approved for PSMA-Positive Prostate Cancer
Web Exclusives published on October 5, 2021 in FDA Updates
Rylaze FDA Approved as Part of a Treatment Regimen for Pediatric Leukemia and Lymphoma
JHOP - August 2021 Vol 11, No 4 published on August 17, 2021 in FDA Updates
FDA Approves Darzalex Faspro plus Pomalyst and Dexamethasone for Multiple Myeloma
Web Exclusives published on August 10, 2021 in FDA Updates
FDA Approves Avapritinib for Advanced Systemic Mastocytosis
Web Exclusives published on August 10, 2021 in FDA Updates
Pembrolizumab plus Lenvatinib Combination Receives Regular Approval for Advanced Endometrial Carcinoma
Web Exclusives published on August 10, 2021 in FDA Updates
Padcev Receives Regular FDA Approval for Locally Advanced or Metastatic Urothelial Cancer
Web Exclusives published on August 10, 2021 in FDA Updates
FDA Alert: Pepaxto (Melphalan Flufenamide) Associated with Increased Risk of Death in Postmarketing Clinical Trial
Web Exclusives published on August 3, 2021 in FDA Updates
Sarclisa Receives New Indication for Relapsed or Refractory Multiple Myeloma
JHOP - June 2021 Vol 11, No 3 published on June 16, 2021 in FDA Updates
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.